Bertrand Tombal, MD, PhD, Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium, provides an overview of the Phase III ARASENS (NCT02799602) trial designed to assess dialuramide plus androgen-deprivation therapy (ADT) and docetaxel for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). Prof. Tombal discusses the results of ARASENS stratified by disease volume and risk. This interview took place at the EAU congress in Milan, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.